Prosecution Insights
Last updated: October 25, 2026
Application No. 18/682,370

PROCESS FOR PREPARING HISTONE DEMETHYLASE INHIBITORS

Non-Final OA §112
Filed
Feb 08, 2024
Priority
Aug 18, 2021 — provisional 63/234,344 +1 more
Examiner
BARSKY, JARED
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Celgene Corporation
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
476 granted / 947 resolved
-9.7% vs TC avg
Strong +23% interview lift
Without
With
+22.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
76 currently pending
Career history
1042
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
49.3%
+9.3% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 947 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim of Foreign Priority Applicant did not claimed foreign priority in the Application Data Sheet filed February 8, 2024. Election/Restrictions Applicant’s election without traverse of Group I, corresponding to claims 78-92, in the reply filed on July 15, 2026, is acknowledged. Applicant elected compound 8 as the species compound for examination. Applicant notes that claims 78-80 encompass the elected species. As such, claims 78-80 are examined below. Status of the Claims Claims 78-93 are pending. Claims 81-93 are withdrawn. Claims 78-80 are examined. The examiner notes that the elected species, compound 8, is taught by Boloor et al., (WO2015200709). Boloor claims the following compound in prior art claim 26. PNG media_image1.png 180 406 media_image1.png Greyscale . Boloor also teaches compound 294, which is shown below as having a nitrile substituted on a claimed core scaffold. PNG media_image2.png 114 230 media_image2.png Greyscale . STN also teaches the following, which is compound 8. PNG media_image3.png 418 682 media_image3.png Greyscale While the synthesized compound is known in the prior art, compound 14 is free of the prior art. As such, a prior art rejection is not applied to reject a method that requires the use of a novel reactant. However, it appears that the instant Specification requires specific steps that are omitted in the claimed methods of synthesizing compound 8. As such, a § 112 rejection is set forth below. The examiner also attaches Wang et al., Chin. J. Org. Chem. 2012, 32, 1643-1652, which represents the state of the art with respect to converting a nitrile to a carboxylic acid. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 78-80 are rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. The disclosure does not enable one of ordinary skill in the art to practice the invention without identifying the steps that provide for producing the claimed product through a process that yields a solid that is easy to filter and dry, and one that is a soluble intermediate for the synthesis of the lysine salt. See par. 146. These are critical or essential to the practice of the invention but not included in the claim(s). See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976). In particular, the hydrolysis of the cyano group was performed to avoid the isolation of the free acid, which is not possible with most common organic solvents. See par. 146. Thus, most common organic solvents are being taught as unusable. This step appears to require EtOH/NaOH (aqueous) 90%. Further, according to paragraph 149 of the Specification, the following steps were required to yield the claimed compound: The final product (Compound 8a) was generated by reaction of Compound 15a with (L)-lysine under acidic conditions. More specifically, to an appropriately sized reactor was charged Compound 15a (559 g, 1.0 wt.) and L-lysine (540 g, 0.966X wt.). The reactor was then purged with Nn, and water (6.99 L, 12.5X vol.) was added. The resulting mixture was then headed (50 °C) and aged (~1 hr). Methanol (2.52 L, 4.5X vol.) was charged in one portion and the reaction was then aged (10 mins). An aqueous solution of2.12M HCl (671 mL, 1.2X vol.) was then charged (over 45 mins) by addition funnel, the mixture was cooled (40 °C), and Compound 8a seed (16 g, 0.03X wt.) was charged. Thus, it is far from clear that the above description is properly and sufficiently captured by the “reacting compound 15, or a solvate thereof, with acid to form compound 8.” As such claims 78-80 are rejected as not providing sufficient specificity in the claims to enable a POSA yield the claimed product. The product that is formed must be sufficient for use in synthesis of the lysine salt. To overcome this rejection Applicant can add specific steps and components to claims 78-80 that are required to produce claimed products. For example, Steps 8 and 9 are shown below: PNG media_image4.png 168 776 media_image4.png Greyscale PNG media_image5.png 156 778 media_image5.png Greyscale The at a minimum the use of EtOH/NaOH 90% and then MeOH/Water/(L)-Lysine, HCl 90% are required by the claimed. The examiner notes that [A] claim which omits matter disclosed to be essential to the invention, as described in the specification or in other statements of record, may also be rejected under 35 U.S.C. § 112(a) as not enabling. {See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976); and MPEP § 2164.08(c)}. As such, no claim is allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JARED D BARSKY whose telephone number is (571)272-2795. The examiner can normally be reached on 9-5 M-F. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Feb 08, 2024
Application Filed
Sep 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767677
LITHIUM DIFLUORO-BIS(OXALATE)PHOSPHATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
2y 10m to grant Granted Oct 20, 2026
Patent 12740947
METHOD OF INITIATING SOTALOL HYDROCHLORIDE DOSING
3y 4m to grant Granted Sep 22, 2026
Patent 12741958
CRYSTAL FORM OF PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR
2y 9m to grant Granted Sep 22, 2026
Patent 12723018
CINNAMOYL AMINO ACID COMPOUND AND USE THEREOF
3y 11m to grant Granted Sep 01, 2026
Patent 12721826
SALT OF A PHARMACEUTICAL COMPOUND
1y 4m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
73%
With Interview (+22.8%)
2y 7m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 947 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month